Trial Profile
[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma to Assess the Feasibility of Targeted Radionuclide Therapy With Somatostatin Receptor Ligands
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Gallium 68-DOTATATE (Primary)
- Indications Liver cancer
- Focus Diagnostic use
- 08 Apr 2022 Status changed from recruiting to completed.
- 20 Mar 2020 Planned End Date changed from 1 Mar 2020 to 31 Dec 2022.
- 20 Mar 2020 Planned primary completion date changed from 1 Mar 2020 to 31 Dec 2021.